Coenzyme Q10 Improves Endothelial Dysfunction in Statin-Treated Type 2 Diabetic Patients

Hamilton, Sandra J.; Chew, Gerard T.; Watts, Gerald F.

doi:10.2337/dc08-1736

Cited by 106 publications

(92 citation statements)

References 15 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 Supplementation with CoQ10 (200 mg/day for 3 months) in type 2 diabetics significantly improved endothelial dysfunction, quantified via brachial artery flow-mediated dilation, translating as a 10-20% reduction in residual cardiovascular risk. 20 Hosseinzadeh-Attar et al 13 found CoQ10 supplementation (200 mg/day for 3 months) significantly reduced circulatory levels of asymmetric dimethylarginine, a marker of endothelial dysfunction and cardiovascular event risk factor. In the Q-SYMBIO study (a randomised double-blind multicentre trial of CoQ10 as adjunctive treatment of chronic heart failure with focus on SYMptoms, BIOmarker status and long-term outcome), supplementation with CoQ10 (300 mg/day for 2 years) improved heart function and reduced cardiovascular-related mortality by 43% in heart failure patients, 10% of whom had type 2 diabetes.…”

Section: Effect Of Coq10 Supplementation On Vascular Dysfunctionmentioning

confidence: 99%

Coenzyme Q10 supplementation for diabetes and its complications: an overview

Mantle¹

2017

Br J Diabetes

View full text Add to dashboard Cite

This article reviews the potential role of dietary supplementation with coenzyme Q10 (CoQ10) for the management of patients with type 2 diabetes. The rationale for supplementation with CoQ10 is based on its key roles in cellular energy metabolism and as an antioxidant, and its potential mediation of oxidative stress and inflammation, which have been implicated in the pathogenesis of diabetes. Randomised controlled clinical trials have demonstrated that supplementation with CoQ10 can significantly improve glycaemic control, as well as improving vascular dysfunction. Supplementation with CoQ10 may be of particular importance in type 2 diabetics prescribed statins and in those with fatty liver disease. Supplemental CoQ10 is usually well tolerated, with no significant adverse effects reported in long-term use. The importance of product quality and bioavailability cannot be over-emphasised, since this may be a factor in the disparity of findings from clinical trials supplementing CoQ10.

show abstract

Section: Effect Of Coq10 Supplementation On Vascular Dysfunctionmentioning

confidence: 99%

Coenzyme Q10 supplementation for diabetes and its complications: an overview

Mantle¹

2017

Br J Diabetes

View full text Add to dashboard Cite

show abstract

“…Given the potential for statins to inhibit the cellular synthesis of plasma CoQ 10 , a by-product of isoprenoid metabolism, their full benefit on improving endothelial function may be blunted [232,233]. In a randomized, double-blind, crossover study, CoQ 10 supplementation significantly improved brachial artery FMD in statin-treated T2D patients with LDLcholesterol <2.5mmol/l and ED [234]. In patients with CAD (20% with diabetes and 80% statin-treated), CoQ 10 supplementation improved ecSOD levels and brachial artery FMD, indicating that the beneficial effects of CoQ 10 on endothelial function are in part related to improvements in local vascular oxidative stress [235].…”

Section: Combination Therapiesmentioning

confidence: 99%

Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment

2013

Self Cite

View full text Add to dashboard Cite

■ AbstractType 2 diabetes (T2D) markedly increases the risk of cardiovascular disease. Endothelial dysfunction (ED), an early indicator of diabetic vascular disease, is common in T2D and independently predicts cardiovascular risk. Although the precise pathogenic mechanisms for ED in T2D remain unclear, at inception they probably involve uncoupling of both endothelial nitric oxide synthase activity and mitochondrial oxidative phosphorylation, as well as the activation of vascular nicotinamide adenine dinucleotide phosphate oxidase. The major contributing factors include dyslipoproteinemia, oxidative stress, and inflammation. Therapeutic interventions are designed to target these pathophysiological factors that underlie ED. Therapeutic interventions, including lifestyle changes, antiglycemic agents and lipid-regulating therapies, aim to correct hyperglycemia and atherogenic dyslipidemia and to improve ED. However, high residual cardiovascular risk is seen in both research and clinical practice settings. Well-designed studies of endothelial function in appropriately selected volunteers afford a good opportunity to test new therapeutic interventions, paving the way for clinical trials and utilization in the care of the diabetic patient. However, based on the results from a recent clinical trial, niacin should not be added to a statin in individuals with low high-density lipoprotein cholesterol and very well controlled low-density lipoprotein cholesterol.

show abstract

“…Specifically, twelve weeks of supplementation with 200mg of CoQ 10 or placebo resulted in significant increases in plasma CoQ 10, respectively, and improved flow mediated dilation (S. J. Hamilton et al, 2009;Watts et al, 2002). However, neither trial found an alteration in biomarkers of oxidative stress or antioxidant capacity, lipid profiles, glycemic control, or blood pressure after supplementation.…”

Section: Coenzyme Q 10mentioning

confidence: 99%